Matches in Wikidata for { <http://www.wikidata.org/entity/Q90076177> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q90076177 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90076177 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90076177 description "scientific article published on 05 March 2020" @default.
- Q90076177 description "wetenschappelijk artikel" @default.
- Q90076177 description "наукова стаття, опублікована 5 березня 2020" @default.
- Q90076177 name "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 name "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 type Item @default.
- Q90076177 label "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 label "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 prefLabel "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 prefLabel "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 P1433 Q90076177-561A19AB-8DA5-4C4D-8232-343A016F331C @default.
- Q90076177 P1476 Q90076177-6CA4836B-A66B-474A-A002-45B3F6A10385 @default.
- Q90076177 P2093 Q90076177-060EEB42-FE67-4965-A63A-30F12C58E34F @default.
- Q90076177 P2093 Q90076177-126C6313-4B78-40F7-83BD-72AAF5250A11 @default.
- Q90076177 P2093 Q90076177-1B64A58E-757D-4135-AA82-EA03D83CE2D2 @default.
- Q90076177 P2093 Q90076177-23438197-8237-4F42-A03F-C1B7C634F2B4 @default.
- Q90076177 P2093 Q90076177-58B02278-ED3D-4A15-9062-4F36A938C9F2 @default.
- Q90076177 P2093 Q90076177-6119305C-10A4-47B4-8BFB-4C2087FC7A52 @default.
- Q90076177 P2093 Q90076177-6120F500-0D61-4AC2-A879-31F90A371AAE @default.
- Q90076177 P2093 Q90076177-93C7C03E-9DD3-4230-9FC3-5E816F2F6D1C @default.
- Q90076177 P2093 Q90076177-A59220C5-E148-4342-8E0F-7FCC824C29B2 @default.
- Q90076177 P2093 Q90076177-C2E5C262-9222-4CF2-BCE9-A2B00A4BC48E @default.
- Q90076177 P2093 Q90076177-DC50FFB1-4AA2-4B37-AE35-B2210D09F4D9 @default.
- Q90076177 P2093 Q90076177-E1DC1C61-89CA-4FFD-834F-C6EF0C43EFD4 @default.
- Q90076177 P2093 Q90076177-FF17F4C7-EE9B-42E5-A8A8-D686A40DA302 @default.
- Q90076177 P2093 Q90076177-FFDAEB6C-D356-48C8-AB87-8763293F3B37 @default.
- Q90076177 P304 Q90076177-80AAE8FD-6C47-46E2-A7B5-109415D0C937 @default.
- Q90076177 P31 Q90076177-B525DAC7-30F6-484F-8B08-EE4DE9E4A52D @default.
- Q90076177 P356 Q90076177-9A2CFE05-02E8-4DB9-B754-E37829BABA2D @default.
- Q90076177 P433 Q90076177-DB88E9A2-5F5A-4C04-96FB-7B37E25C5FB8 @default.
- Q90076177 P478 Q90076177-71592B5F-ED58-4C15-A063-645897B692B2 @default.
- Q90076177 P50 Q90076177-500CCB10-41F0-4D8A-80E9-EAFBE28B2493 @default.
- Q90076177 P50 Q90076177-BF40E448-FE2B-4E8C-AEBC-06DBEC619C85 @default.
- Q90076177 P577 Q90076177-29FCD9D3-5DA4-4795-B554-86D32F61F46D @default.
- Q90076177 P698 Q90076177-A10B23EC-689B-41A5-9F05-012502521DD6 @default.
- Q90076177 P921 Q90076177-6377EDD3-254E-4F70-82E5-C419FB81C3CD @default.
- Q90076177 P921 Q90076177-8CECADBF-D4E5-4CAE-A347-DA6F884228AD @default.
- Q90076177 P921 Q90076177-D9627200-A2B4-4594-9357-49F6C17E475D @default.
- Q90076177 P356 0956462419896478 @default.
- Q90076177 P698 32138618 @default.
- Q90076177 P1433 Q15716692 @default.
- Q90076177 P1476 "Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients" @default.
- Q90076177 P2093 "Alberto Diaz De Santiago" @default.
- Q90076177 P2093 "Alfonso Cabello" @default.
- Q90076177 P2093 "Alvaro Mena" @default.
- Q90076177 P2093 "BIRDi study group" @default.
- Q90076177 P2093 "Jorge Vergas" @default.
- Q90076177 P2093 "José L Blanco" @default.
- Q90076177 P2093 "Juan C Lopez" @default.
- Q90076177 P2093 "Maria J Galindo" @default.
- Q90076177 P2093 "Marta Montero" @default.
- Q90076177 P2093 "Miguel García Deltoro" @default.
- Q90076177 P2093 "Nuria Espinosa" @default.
- Q90076177 P2093 "Pilar Vizcarra" @default.
- Q90076177 P2093 "Rocío Montejano" @default.
- Q90076177 P2093 "Rosario Palacios" @default.
- Q90076177 P304 "467-473" @default.
- Q90076177 P31 Q13442814 @default.
- Q90076177 P356 "10.1177/0956462419896478" @default.
- Q90076177 P433 "5" @default.
- Q90076177 P478 "31" @default.
- Q90076177 P50 Q47006508 @default.
- Q90076177 P50 Q87367413 @default.
- Q90076177 P577 "2020-03-05T00:00:00Z" @default.
- Q90076177 P698 "32138618" @default.
- Q90076177 P921 Q1414874 @default.
- Q90076177 P921 Q3765251 @default.
- Q90076177 P921 Q421552 @default.